Howard Is A 24-Year-Old Male Who Presents To The Clinic With

Howard Is A 24 Year Old Male Who Presents To The Clinic With His Wife

Howard is a 24-year-old male presenting to the clinic with severe lower back pain following a history of a car accident in 2012. He reports the pain as a "50 out of 10" and states it flares up periodically, requiring pain medication. Due to a past ulcer, he cannot take NSAIDs like Motrin. He has a high pain tolerance and needs higher doses of pain medications when needed. His medical history raises important considerations regarding pain management, especially with regard to medication safety, patient education, potential substance use disorder, and coordinated care with specialists.

Paper For Above instruction

The management of acute and chronic pain, particularly in patients with a history of substance use or vulnerabilities such as previous ulcer disease, requires a comprehensive approach. The first step involves a thorough assessment, including evaluating the severity and impact of pain, current medical history, medication allergies, and potential for substance misuse. It’s essential to perform a detailed pain assessment and review the patient’s medication history, including recent prescriptions and any history of medication or substance use disorders.

Before prescribing any medication, a healthcare provider must evaluate the patient’s risk factors for misuse or addiction and consider non-pharmacologic interventions. In terms of medication scheduling, controlled substances are classified into schedules I through V according to the DEA, based on their potential for abuse and medical utility. Schedule I substances have no accepted medical use and a high potential for abuse, whereas Schedule V drugs have the lowest potential for dependence and accepted medical uses. Most opioids prescribed for pain management fall into Schedule II or III, as they carry high or moderate potential for abuse.

When considering opioid therapy, clinicians typically opt for short-acting opioids initially, especially when managing episodic or flare-up pain. However, in chronic pain settings, long-acting opioids can be considered for baseline pain control, with short-acting agents available for breakthrough pain. Given Howard’s history, a short-acting opioid might provide better control with less risk of accumulation, though in some cases, long-acting opioids could be appropriate if pain is persistent and severe, with careful monitoring. The decision should be individualized, considering the patient's pain severity, history of tolerance, and risk factors for misuse.

Non-narcotic treatment options are crucial, especially given Howard’s history. Non-pharmacological approaches include physical therapy, chiropractic care, acupuncture, psychological therapies such as cognitive-behavioral therapy (CBT), and activity modifications. Pharmacological alternatives include adjuvant medications such as anticonvulsants (e.g., gabapentin), antidepressants (e.g., duloxetine), muscle relaxants, or topical agents. Patient education must include the rationale for multimodal pain management, medication risks, non-drug therapies, and setting realistic expectations for pain control. If these alternatives prove ineffective, it is critical to reassess the diagnosis, consider referral to specialists, or explore interventional procedures such as epidural injections, especially since Howard is already under care from a pain specialist.

If Howard and his wife report that non-opioid options are ineffective, further assessment is necessary. This includes evaluating for neuropathic pain, psychological factors associated with pain perception, and potential barriers to alternative therapies. Involving multidisciplinary teams can optimize outcomes, and supporting the patient through behavioral health interventions is often beneficial. Ensuring a comprehensive, patient-centered approach reduces risks associated with opioid therapy and manages pain more effectively.

Screening for substance use disorder is a crucial component of management. Validated tools such as the Alcohol Use Disorders Identification Test (AUDIT), Drug Abuse Screening Test (DAST), or the Opioid Risk Tool (ORT) provide reliable assessments of potential misuse. Urine drug screening (UDS) offers objective evidence of substance use but should be used judiciously within a comprehensive assessment. If Howard screens positive or admits to a substance use disorder, strategies include motivational interviewing, brief interventions, and referral to addiction specialists or treatment programs.

Referral pathways should include substance abuse treatment programs such as medication-assisted treatment (MAT), inpatient detoxification, or outpatient addiction management, depending on severity. Evidence-based options like buprenorphine/naloxone or methadone can be prescribed by trained clinicians for opioid use disorder, with specific regulatory and contractual requirements for nurse practitioners, including completion of specialized training and adherence to state and federal regulations. For patients enrolled in MAT, ongoing monitoring, counseling, and compliance with program protocols are essential for sustained recovery.

In Howard’s case, detection of opioid dependence necessitates a coordinated approach involving addiction specialists, mental health providers, and case management. Education about relapse prevention, overdose risks, and medication adherence is critical. The involvement of family members, especially his wife, supports treatment adherence and emotional stabilization. Pharmacological options such as buprenorphine or methadone may be appropriate, with close supervision and regulatory adherence. Nonpharmacological support includes counseling, behavioral therapies, and peer support groups to address underlying psychological and social factors contributing to substance misuse.

In conclusion, managing Howard’s complex pain and potential opioid use disorder requires a multidisciplinary, patient-centered approach. Judicious prescribing, thorough assessment, education, and appropriate referrals are essential to balance effective pain relief and minimize the risk of misuse and overdose. Integrating pharmacologic and nonpharmacologic strategies, along with ongoing monitoring, can optimize outcomes for patients facing chronic pain and substance use challenges.

References

  • Centers for Disease Control and Prevention. (2022). CDC Guideline for Prescribing Opioids for Pain. Morbidity and Mortality Weekly Report, 71(1), 1–95.
  • Volkow, N. D., & McLellan, A. T. (2016). The Role of Science in Addressing the Opioid Crisis. New England Journal of Medicine, 375(4), 391–394.
  • National Institute on Drug Abuse. (2021). Injectable Opioid Agonist Treatment (iOAT). https://www.drugabuse.gov/publications/drugfacts/injectable-opioid-agonist-treatment
  • Kreuzberger, R., et al. (2020). Multimodal Pain Management for Chronic Pain. Journal of Pain Research, 13, 2715–2727.
  • Substance Abuse and Mental Health Services Administration. (2020). Medication-Assisted Treatment (MAT). https://www.samhsa.gov/medication-assisted-treatment
  • Sharma, A., et al. (2018). Pharmacological Strategies for Chronic Pain. Curr Treat Opt Pain, 24(6), 22.
  • Bradshaw, J. L., & Morselli, M. (2019). Non-Pharmacological Approaches to Pain Management. Current Pain and Headache Reports, 23, 64.
  • Butler, S. F., et al. (2017). Screening and Interventions for Substance Use Disorders in Pain Clinics. Pain Medicine, 18(4), 671–680.
  • American Society of Interventional Pain Physicians. (2019). Guidelines for Epidural Injections. https://asimpp.org/
  • O’Connor, P. G., et al. (2019). Managing Opioid Use Disorder in Primary Care. JAMA, 321(10), 957–958.

Related Assignments